A detailed history of Stifel Financial Corp transactions in Nkarta, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 81,452 shares of NKTX stock, worth $188,154. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,452
Previous 78,401 3.89%
Holding current value
$188,154
Previous $463,000 20.52%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.52 - $8.0 $13,790 - $24,408
3,051 Added 3.89%
81,452 $368,000
Q2 2024

Aug 13, 2024

SELL
$5.27 - $10.82 $81,858 - $168,067
-15,533 Reduced 16.54%
78,401 $463,000
Q1 2024

May 13, 2024

SELL
$5.59 - $15.71 $633,514 - $1.78 Million
-113,330 Reduced 54.68%
93,934 $1.02 Million
Q4 2023

Feb 12, 2024

SELL
$1.31 - $6.6 $418,364 - $2.11 Million
-319,362 Reduced 60.64%
207,264 $1.37 Million
Q3 2023

Nov 13, 2023

BUY
$1.39 - $2.29 $365,989 - $602,961
263,302 Added 99.99%
526,626 $732,000
Q2 2023

Aug 14, 2023

BUY
$2.19 - $5.17 $193,679 - $457,224
88,438 Added 50.57%
263,324 $576,000
Q1 2023

May 12, 2023

BUY
$3.37 - $6.3 $175,903 - $328,841
52,197 Added 42.54%
174,886 $620,000
Q4 2022

Feb 13, 2023

BUY
$5.14 - $14.35 $444,779 - $1.24 Million
86,533 Added 239.33%
122,689 $734,000
Q3 2022

Nov 14, 2022

BUY
$12.27 - $18.39 $211,289 - $316,675
17,220 Added 90.94%
36,156 $476,000
Q2 2022

Aug 15, 2022

SELL
$7.77 - $19.44 $989,152 - $2.47 Million
-127,304 Reduced 87.05%
18,936 $233,000
Q1 2022

May 13, 2022

BUY
$8.66 - $14.99 $414,138 - $716,851
47,822 Added 48.59%
146,240 $1.66 Million
Q4 2021

Feb 14, 2022

BUY
$12.79 - $26.88 $1.26 Million - $2.65 Million
98,418 New
98,418 $1.51 Million

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $112M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.